Regentis Biomaterials Ltd. (NYSE American: RGNT) announced on July 20 that it has received a notice of allowance from the Japan Patent Office for a patent covering its organic solvent-free manufacturing process and ready-to-use liquid formulation for GelrinC, its cell-free hydrogel for knee cartilage repair. This development follows a recent U.S. patent grant and extends the company’s intellectual property footprint into Japan, one of the world’s largest cartilage-repair markets.
The allowed patent claims protect the innovative manufacturing process that yields a five-fold increase in production efficiency compared to traditional methods, along with simplified production steps and enhanced commercial scalability. This is a critical advantage for GelrinC, which is designed to be an off-the-shelf product that can be administered in a single procedure of about 10 minutes, without the need for cell harvesting or laboratory processing.
Dr. Jonathan Roth, CEO of Regentis, emphasized the importance of this milestone: “This patent allowance underscores our commitment to building a robust intellectual property estate around our unique manufacturing process and product formulation. It is a key element of our strategy to establish GelrinC as a leading therapy in the global cartilage repair market.”
The announcement comes at a pivotal time for Regentis as it advances European commercialization and has passed the halfway mark in enrollment for its pivotal U.S. clinical trial. The company is positioning itself to address a significant unmet medical need, as aging populations and rising joint disease prevalence drive demand for effective and economically viable cartilage repair solutions.
Current treatment options, such as microfracture and autologous chondrocyte implantation, have shown clinical utility but are often limited by high costs, complex procedures, and variable outcomes. GelrinC aims to overcome these barriers with its off-the-shelf availability and streamlined manufacturing process, which could make large-scale production and distribution economically feasible.
The strengthened IP protection is expected to provide a competitive moat for Regentis, safeguarding its proprietary technology in key markets. The company’s manufacturing process not only improves yield but also eliminates organic solvents, potentially enhancing product safety and regulatory acceptance.
As Regentis moves forward, the combination of clinical progress and a solid intellectual property foundation positions the company to capture a significant share of the cartilage repair market. With the Japanese patent allowance, Regentis reinforces its global presence and commitment to delivering innovative solutions for patients suffering from knee cartilage damage.
For more information on Regentis Biomaterials and its latest developments, visit the company’s newsroom at ibn.fm/RGNT.
